Johnson & Johnson (JNJ.US) stock rose 1.5% after the U.S. FDA endorsed the drugmaker's one-shot Covid-19 vaccine which appeared safe and effective in trials. New data showed the vaccine was 64% effective at stopping moderate to severe cases of COVID-19 after 28 days in thousands of trial participants in South Africa where a new variant has swept across the country. Overall, the vaccine was 100% effective at stopping hospitalization 28 days after vaccination, compared with 85% at 14 days, and there were no COVID-19 deaths among those who received the shot rather than a placebo. FDA’s Vaccines and Related Biological Products Advisory Committee, will meet on Friday to review company's request for emergency use authorization.

TSMC Earnings Preview: Will the Key Semiconductor Supplier Surprise the Market?
US Open: American Indices Rally on Anticipated End of Fed Balance Sheet Reduction
Bank of America, Wells Fargo, and Morgan Stanley: Q3 2025 Earnings Overview
Abbott reports no surprises in Q3, but tariff risks and lowered forecasts drag the share price down💡